KBC Group’s 10x Genomics TXG Stock Holding History

KBC Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$79K	Sell	3,714 -1,358	-27%	-$27.1K	﹤0.01%	1462
2025 Q4	$83K	Hold	5,072	–	–	﹤0.01%	1406
2025 Q3	$59K	Hold	5,072	–	–	﹤0.01%	1590
2025 Q2	$59K	Hold	5,072	–	–	﹤0.01%	1526
2025 Q1	$44K	Hold	5,072	–	–	﹤0.01%	1815
2024 Q4	$73K	Buy	5,072 +1,847	+57%	+$29.1K	﹤0.01%	1717
2024 Q3	$73K	Buy	3,225 +902	+39%	+$18.6K	﹤0.01%	1498
2024 Q2	$45K	Hold	2,323	–	–	﹤0.01%	1682
2024 Q1	$87K	Buy	2,323 +473	+26%	+$20.8K	﹤0.01%	1205
2023 Q4	$104K	Hold	1,850	–	–	﹤0.01%	1052
2023 Q3	$76K	Buy	+1,850	New	+$96.2K	﹤0.01%	1138
2022 Q4	–	Sell	-850	Closed	-$24K	–	1554
2022 Q3	$24K	Hold	850	–	–	﹤0.01%	1501
2022 Q2	$38K	Sell	850 -5,272	-86%	-$274K	﹤0.01%	1468
2022 Q1	$466K	Hold	6,122	–	–	﹤0.01%	834
2021 Q4	$912K	Buy	6,122 +1,560	+34%	+$239K	﹤0.01%	734
2021 Q3	$664K	Sell	4,562 -4,562	-50%	-$783K	﹤0.01%	816
2021 Q2	$1.79M	Hold	9,124	–	–	﹤0.01%	785
2021 Q1	$1.65M	Hold	9,124	–	–	﹤0.01%	782
2020 Q4	$7.11M	Buy	+9,124	New	+$1.32M	﹤0.01%	815

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KBC Group's TXG Position: Q1 2026 in Review

KBC Group reduced its 10x Genomics (TXG) stake by 27% in Q1 2026, selling an estimated $27.1K and leaving 3,714 shares worth $79K. The position accounts for ﹤0.01% of the portfolio, ranked #1462.

KBC Group first reported a position in TXG in Q4 2020 and has held it in 19 quarters since. The position peaked at $7.11M in Q4 2020. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

KBC Group held 3,714 shares of 10x Genomics worth $79K as of Q1 2026.
KBC Group sold 1,358 10x Genomics shares in Q1 2026, an estimated $27.1K.
10x Genomics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1462 holding.
KBC Group first reported a position in 10x Genomics in Q4 2020 and has held it in 19 quarters since.
KBC Group's 10x Genomics position peaked at $7.11M in Q4 2020.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.